Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years

Annals of Surgery

Volumn 235, Issue 1, 2002, Pages 10-26

  Mirza, Attiqa N ^a   Mirza, Nadeem Q ^a   Vlastos, Georges ^a   Singletary, Eva S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; MITOSIS; MITOSIS INDEX; ONCOGENE C MYC; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SAMPLE; TUMOR VOLUME;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CATHEPSIN D; DISEASE-FREE SURVIVAL; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KI-67 ANTIGEN; LYMPH NODES; MITOTIC INDEX; MULTIVARIATE ANALYSIS; MUTATION; PLOIDIES; PROBABILITY; PROGNOSIS; RECEPTORS, ESTROGEN; RISK; RISK FACTORS; S PHASE; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036141136     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200201000-00003     Document Type: Review

References (88)

1. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer
2. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma
3. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases
4. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999
5. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer
6. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
7. The relationship between prognostic and predictive factors in the management of breast cancer
8. Prognostic factors in early breast carcinoma
9. Prognostic factors for patients with breast cancers 1 cm and smaller
10. Tumor markers for breast cancer
11. Relationship between p53 gene abnormalities and other tumor characteristics in breast cancer prognosis
12. Mitotic indexes as prognostic predictors in female breast cancer
13. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma
14. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer
15. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor
16. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: Analysis of clinicopathological prognostic factors
17. Comparison of mitotic index, in vitro bromodeoxyuridine labeling and MIB-1 assays to quantitate proliferation in breast cancer
18. Relative worth of estrogen or progesterone receptor and pathological characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06
19. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients
20. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers
21. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer
22. Ki 67, p53, ER receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer
23. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node negative breast cancer patients
24. p53 as an independent prognostic markers in lymph node negative breast cancer patients
25. Prognostic significance of p53, angiogensis and other conventional features in operable breast cancer: Sub analysis in node-positive and node-negative patients
26. p53 determination alongside classical prognostic factors in node negative breast cancer: An evaluation at more than 10-year follow-up
27. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer
28. Prognostic significance of p53 gene alterations in node negative breast cancer
29. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
30. Correlation between p53, c-erbB-2, and topoisomerase IIa expression, DNA ploidy, hormonal receptor status and proliferation in 356 node negative breast carcinomas: Prognostic implications
31. Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases
32. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?
33. Enzyme-linked immunoabsorbent asssay-detected p53 protein accumulation: A prognostic factor in a large breast cancer cohort
34. An immunohistochemical study of p53 with correlation to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen and prognosis
35. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicenter study
36. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis
37. Prognostic significance of HER2/neu expression in breast cancer and its relationship to other prognostic factors
38. The long-term prognostic significance of c-erbB-2 in primary breast cancer
39. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - An immunocytochemical study
40. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: A study of epidemiologic risk factors, histologic features, and prognosis
41. The prognostic value of c-erbB-2 in primary breast carcinomas: A study on 942 cases
42. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
43. Prognostic importance of c-erbB-2 expression in breast cancer
44. c-erb B-2 oncoprotein expression in primary and advanced breast cancer
45. HER2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
46. Prognostic significance of c-erbB-2 expression in node-negative breast cancer
47. HER2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
48. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node negative breast cancer
49. Cathepsin D in primary breast cancer: Prognostic evaluation involving 2810 patients
50. Prognostic value of total cathepsin D in breast tumors: A possible role in selection of chemoresistent patients
51. Relationship between cathepsin-D content and disease-free survival in node negative breast cancer patients
52. Prognostic value of Ki-67 compared to S-phase fraction in axillary node negative breast cancer
53. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas
54. Flow cytometric DNA ploidy defines patients with poor prognosis in node negative breast cancer
55. Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinoma: 10 year survival study
56. S-phase fraction is a prognostic factor in stage I breast carcinoma
57. S-phase fraction combined with patient and tumor characteristics for the prognosis of node-negative estrogen-receptor-positive breast cancer
58. S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer
59. The utility of mitotic index, estrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer
60. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast
61. Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large study with long-term follow-up
62. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer
63. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer
64. Update of recommendations for the use of tumor markers in breast and colorectal cancer
65. Breast
66. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
67. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
68. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
69. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
70. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables
71. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
72. Prognostic and predictive significance of erbB-2 breast tumor levels measured by enzyme immunoassay
73. Cathepsin-D and prognosis in breast cancer
74. Cathepsin D by western blotting and immunohistochemistry: Failure to confirm correlations with prognosis in node-negative breast cancer
75. HER2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
76. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization in the Herceptin pivotal trials
77. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients
78. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
79. Prognostic and predictive value of p53 and p21 in breast cancer
80. Cripto: A novel epidermal growth factor-related peptide in mammary gland development and neoplasia
81. Roles of the matrix metalloproteinases in mammary gland development and cancer
82. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
83. Familial breast cancer, family cancer syndromes, and predisposition to breast neoplasia
84. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
85. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
86. Survival in hereditary breast cancer associated with germline mutations of BRCA2
87. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
88. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden